Neoadjuvant chemo-immunotherapy plus/minus fasting-like approach in stage II-III triple-negative breast cancer patients: The phase II randomized BREAKFAST-2 trial

被引：1
|
作者：
Vernieri, C. [1 ]
Ligorio, F. [1 ]
Dieci, M. V. [2 ]
Lambertini, M. [3 ]
De Angelis, C. [4 ]
Iorfida, M. [5 ]
Botticelli, A. [6 ]
Strina, C. [7 ]
Vingiani, A. [8 ]
Provenzano, L. [1 ]
Bianchi, G. V. [1 ]
Folli, S. [9 ]
Generali, D.
Zambelli, A. [10 ]
de Placido, S. [4 ]
Del Mastr, L. [3 ]
Guarneri, V. [2 ]
Capri, G. [1 ]
Pruneri, G. [8 ]
De Braud, F. G. M. [1 ]
机构：
[1] Fdn IRCCS, Ist Nazl Tumori, Med Oncol & Hematol Dept, Milan, Italy
[2] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy
[3] IRCCS AOU San Martino, Dept Med Oncol, Ist Nazl Ric Cancro, IST, Genoa, Italy
[4] Azienda Osped Univ Federico II, Dept Clin Med & Surg, Naples, Italy
[5] European Inst Oncol, IEO, Div Med Senol, Milan, Italy
[6] Sapienza Univ Rome, Dept Radiol Oncol & Pathol Sci, Rome, Italy
[7] ASST Cremona, Multidisciplinary Unit Breast Pathol & Translat, Cremona, Italy
[8] Fdn IRCCS, Ist Nazl Tumori, Dept Adv Diagnost, Milan, Italy
[9] Fdn IRCCS, Ist Nazl Tumori, Breast Unit, Milan, Italy
[10] Humanitas Univ, Dept Biomed Sci, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2829
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
352TiP
引用
收藏
页码：S322 / S323
页数：2
相关论文
共 50 条
  • [1] A randomized phase II neoadjuvant trial in patients with stage II-III and inflammatory breast cancer
    Somlo, G.
    Paz, B.
    Shen, J.
    Garberoglio, C.
    Luu, T.
    Chung, C.
    Hurria, A.
    Frankel, P.
    Baker, N.
    Wilczynski, S.
    Arnold, K.
    Yeb, Y.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S231 - S231
  • [2] Targeting triple-negative breast cancer metabolism with neoadjuvant chemotherapy plus fasting-mimicking diet plus/minus metformin: The BREAKFAST trial
    Ligorio, F.
    Fuca, G.
    Vingiani, A.
    Iannelli, F.
    Lobefaro, R.
    Ferraris, C.
    Belfiore, A.
    Scaperrotta, G.
    Depretto, C.
    Martinetti, A.
    Corsetto, P.
    Bianchi, G. V.
    Capri, G.
    Folli, S.
    Minucci, S.
    Foiani, M.
    Pagani, M.
    Pruneri, G.
    De Braud, F. G. M.
    Vernieri, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S282 - S283
  • [3] Neoadjuvant phase II trial with eribulin and carboplatin in patients with triple-negative breast cancer
    Giordano, Sara Barnato
    Rao, Shreyas
    Hamdan, Randala
    Jeruss, Jacqueline
    Bethke, Kevin
    Hansen, Nora
    Khan, Seema
    Von Roenn, Jamie
    Rosen, Steven
    Gradishar, William J.
    Siziopikou, Kalliopi
    Meservey, Caitlin
    Kaklamani, Virginia
    MOLECULAR CANCER RESEARCH, 2013, 11
  • [4] Predictors of Pathologic Complete Response with Neoadjuvant Chemo-Immunotherapy in Early-Stage Triple-Negative Breast Cancer
    Perry, Lauren M.
    Sevilimedu, Varadan
    Polidorio, Natalia
    Abuhadra, Nour
    Morrow, Monica
    Plitas, George
    Downs-Canner, Stephanie
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S102 - S102
  • [5] Metformin with neoadjuvant chemotherapy in stage II-III breast cancer: A phase II clinical trial
    Azazy, H. A.
    Gado, N. M.
    Salem, D. A.
    El-Ghamry, W. R.
    ANNALS OF ONCOLOGY, 2020, 31 : S323 - S324
  • [6] Phase II neoadjuvant trial with carboplatin and eribulin mesylate in patients with triple-negative breast cancer
    Barnato, Sara E.
    Jeruss, Jacqueline Sara
    Bethke, Kevin P.
    Hansen, Nora M.
    Khan, Seema Ahsan
    Von Roenn, Jamie H.
    Rosen, Steven T.
    Gradishar, William John
    Siziopikou, Kalliopi P.
    Meservey, Caitlin
    Kaklamani, Virginia G.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus (an mTOR inhibitor) in patients with stage II/III triple-negative breast cancer (TNBC)
    Mayer, I. A.
    Jovanovic, B.
    Abramson, V. G.
    Mayer, E. L.
    Sanders, M. E.
    Bardia, A.
    Dillon, P. M.
    Kuba, M. G.
    Carpenter, J. T.
    Chang, J. C.
    Lehmann, B. D.
    Meszoely, I. M.
    Grau, A.
    Shyr, Y.
    Arteaga, C. L.
    Chen, X.
    Pietenpol, J. A.
    CANCER RESEARCH, 2013, 73
  • [8] Postmastectomy radiotherapy reduces locoregional and disease recurrence in patients with stage II-III triple-negative breast cancer treated with neoadjuvant chemotherapy and mastectomy
    Chen, Xingxing
    Xia, Fan
    Luo, Jurui
    Ma, Jinli
    Yang, Zhaozhi
    Zhang, Li
    Feng, Yan
    Shao, Zhimin
    Yu, Xiaoli
    Guo, Xiaomao
    ONCOTARGETS AND THERAPY, 2018, 11 : 1973 - 1980
  • [9] Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer
    Yuan, Yuan
    Lee, Jin Sun
    Yost, Susan E.
    Li, Sierra Min
    Frankel, Paul H.
    Ruel, Christopher
    Schmolze, Daniel
    Robinson, Kim
    Tang, Aileen
    Martinez, Norma
    Stewart, Daphne
    Waisman, James
    Kruper, Laura
    Jones, Veronica
    Menicucci, Andrea
    Uygun, Sahra
    Yoder, Erin
    van der Baan, Bastiaan
    Yim, John H.
    Yeon, Christina
    Somlo, George
    Mortimer, Joanne
    ONCOLOGIST, 2021, 26 (03): : E382 - E393
  • [10] Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial
    Cristiano de Pádua Souza
    Ana Suellen Barroso Carneiro
    Ana Cecília de Oliveira Lessa
    Domício Carvalho Lacerda
    Carlos Eduardo Paiva
    Marina Moreira Costa Zorzetto
    Ana Julia Aguiar de Freitas
    Iara Viana Vidigal Santana
    Marco Antonio de Oliveira
    Edenir Inêz Palmero
    Márcia Maria Chiquitelli Marques
    Tomás Reinert
    Breast Cancer Research and Treatment, 2023, 202 : 57 - 65
12345